Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
暂无分享,去创建一个
P. Vyas | B. Skikne | G. Garcia-Manero | D. Niederwieser | P. Fenaux | A. Giagounidis | F. Buccisano | U. Platzbecker | M. Mittelman | V. Santini | J. Shortt | J. Zhong | R. Buckstein | D. E. Lopes de Menezes | L. Silverman | A. Jonasova | G. Reda | E. Olíva | A. Almeida | D. Valcárcel | L. Fianchi | J. Falantes | S. Larsen | E. Laille | C. Beach | V. Giai | I. La Torre | M. Diez Campelo | A. Jonášová
[1] M. Cazzola,et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. , 2020, The New England journal of medicine.
[2] G. Garcia-Manero,et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. , 2019, Blood.
[3] B. Skikne,et al. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. , 2018, Leukemia research.
[4] K. Götze,et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS , 2018, Leukemia.
[5] M. Delforge,et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes , 2017, Leukemia.
[6] A. Stamatoullas,et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. , 2017, The Lancet. Haematology.
[7] R. Bejar. Implications of molecular genetic diversity in myelodysplastic syndromes , 2017, Current opinion in hematology.
[8] B. Skikne,et al. CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies , 2016 .
[9] A. Tefferi,et al. Myelodysplastic syndromes: Contemporary review and how we treat , 2016, American journal of hematology.
[10] B. Skikne,et al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes , 2015, Leukemia.
[11] B. Skikne,et al. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies , 2015, PloS one.
[12] C. Jung,et al. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients , 2015, Oncotarget.
[13] D. Neuberg,et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.
[14] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[15] Y. Saunthararajah. Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. , 2013, Hematology. American Society of Hematology. Education Program.
[16] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[17] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[18] M. Ardanaz,et al. Prognostic impact of severe thrombocytopenia in low‐risk myelodysplastic syndrome , 2011, Cancer.
[19] E. Vellenga,et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme , 2011, British journal of haematology.
[20] B. Skikne,et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Kantarjian,et al. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. , 2011, Clinical lymphoma, myeloma & leukemia.
[22] R. Larson,et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[24] F. Lyko,et al. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.
[25] M. Cazzola,et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[27] J. Cashy,et al. General Population and Cancer Patient Norms for the Functional Assessment of Cancer Therapy-General (FACT-G) , 2005, Evaluation & the health professions.
[28] M. Essink‐bot,et al. Quality of life measurement in patients with transfusion‐dependent myelodysplastic syndromes , 2003, British journal of haematology.
[29] J. Issa,et al. Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications , 2001, Annals of Internal Medicine.
[30] D. Cella,et al. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. , 1997, Seminars in hematology.
[31] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.